APO Research
Talk to an analyst

APO RESEARCH · REPORT

Myasthenia Gravis Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Myasthenia Gravis Drugs Market Analysis and Forecast 2026-2032

26 December 2025203 pages

Choose your research edition.

Industry ResearchMyasthenia Gravis Drugs Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Myasthenia Gravis Drugs Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal Myasthenia Gravis Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Myasthenia Gravis Drugs Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Myasthenia Gravis Drugs Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global Myasthenia Gravis Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Myasthenia Gravis Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Myasthenia Gravis Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Myasthenia Gravis Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Myasthenia Gravis Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Myasthenia Gravis Drugs include Alexion Pharmaceuticals, Bausch Health, Catalyst Pharmaceuticals, CSL, Curavac, Cytokinetics, F. Hoffmann-La Roche, Flamel Technologies and Galencia, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Myasthenia Gravis Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Myasthenia Gravis Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Myasthenia Gravis Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Myasthenia Gravis Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Myasthenia Gravis Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Myasthenia Gravis Drugs sales, projected growth trends, production technology, application and end-user industry.

Myasthenia Gravis Drugs Segment by Company

Alexion Pharmaceuticals

Bausch Health

Catalyst Pharmaceuticals

CSL

Curavac

Cytokinetics

F. Hoffmann-La Roche

Flamel Technologies

Galencia

GlaxoSmithKline

Grifols

Lupin Pharmaceuticals

Mitsubishi Tanabe Pharma

Pfizer

Novartis

Takeda

Myasthenia Gravis Drugs Segment by Type

Intravenous Immune Globulins

Anticholinesterases

Immunosuppressants

Myasthenia Gravis Drugs Segment by Application

Hospitals

Clinics

Myasthenia Gravis Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Myasthenia Gravis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Myasthenia Gravis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Myasthenia Gravis Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Myasthenia Gravis Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Myasthenia Gravis Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Myasthenia Gravis Drugs sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Myasthenia Gravis Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Intravenous Immune Globulins Major Manufacturers Table 3. Anticholinesterases Major Manufacturers Table 4. Immunosuppressants Major Manufacturers Table 5. Global Myasthenia Gravis Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospitals Major Manufacturers Table 7. Clinics Major Manufacturers Table 8. Myasthenia Gravis Drugs Industry Trends Table 9. Myasthenia Gravis Drugs Industry Drivers Table 10. Myasthenia Gravis Drugs Industry Opportunities and Challenges Table 11. Myasthenia Gravis Drugs Industry Restraints Table 12. Global Myasthenia Gravis Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global Myasthenia Gravis Drugs Revenue by Region (2021-2026) & (US$ Million) Table 14. Global Myasthenia Gravis Drugs Revenue by Region (2027-2032) & (US$ Million) Table 15. Global Myasthenia Gravis Drugs Revenue Market Share by Region (2021-2026) Table 16. Global Myasthenia Gravis Drugs Revenue Market Share by Region (2027-2032) Table 17. Global Myasthenia Gravis Drugs Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (Tons) Table 18. Global Myasthenia Gravis Drugs Sales by Region (2021-2026) & (Tons) Table 19. Global Myasthenia Gravis Drugs Sales by Region (2027-2032) & (Tons) Table 20. Global Myasthenia Gravis Drugs Sales Market Share by Region (2021-2026) Table 21. Global Myasthenia Gravis Drugs Sales Market Share by Region (2027-2032) Table 22. Global Myasthenia Gravis Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global Myasthenia Gravis Drugs Revenue Market Share by Manufacturers (2021-2026) Table 24. Global Myasthenia Gravis Drugs Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Myasthenia Gravis Drugs Sales Market Share by Manufacturers (2021-2026) Table 26. Global Myasthenia Gravis Drugs Sales Price (US$/Kg) of Manufacturers (2021-2026) Table 27. Global Myasthenia Gravis Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global Myasthenia Gravis Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global Myasthenia Gravis Drugs Manufacturers, Product Type & Application Table 30. Global Myasthenia Gravis Drugs Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global Myasthenia Gravis Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global Myasthenia Gravis Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Myasthenia Gravis Drugs Revenue by Type (2021-2026) & (US$ Million) Table 35. Global Myasthenia Gravis Drugs Revenue by Type (2027-2032) & (US$ Million) Table 36. Global Myasthenia Gravis Drugs Revenue Market Share by Type (2021-2026) Table 37. Global Myasthenia Gravis Drugs Revenue Market Share by Type (2027-2032) Table 38. Global Myasthenia Gravis Drugs Sales by Type 2021 VS 2025 VS 2032 (Tons) Table 39. Global Myasthenia Gravis Drugs Sales by Type (2021-2026) & (Tons) Table 40. Global Myasthenia Gravis Drugs Sales by Type (2027-2032) & (Tons) Table 41. Global Myasthenia Gravis Drugs Sales Market Share by Type (2021-2026) Table 42. Global Myasthenia Gravis Drugs Sales Market Share by Type (2027-2032) Table 43. Global Myasthenia Gravis Drugs Price by Type (2021-2026) & (US$/Kg) Table 44. Global Myasthenia Gravis Drugs Price by Type (2027-2032) & (US$/Kg) Table 45. Global Myasthenia Gravis Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Myasthenia Gravis Drugs Revenue by Application (2021-2026) & (US$ Million) Table 47. Global Myasthenia Gravis Drugs Revenue by Application (2027-2032) & (US$ Million) Table 48. Global Myasthenia Gravis Drugs Revenue Market Share by Application (2021-2026) Table 49. Global Myasthenia Gravis Drugs Revenue Market Share by Application (2027-2032) Table 50. Global Myasthenia Gravis Drugs Sales by Application 2021 VS 2025 VS 2032 (Tons) Table 51. Global Myasthenia Gravis Drugs Sales by Application (2021-2026) & (Tons) Table 52. Global Myasthenia Gravis Drugs Sales by Application (2027-2032) & (Tons) Table 53. Global Myasthenia Gravis Drugs Sales Market Share by Application (2021-2026) Table 54. Global Myasthenia Gravis Drugs Sales Market Share by Application (2027-2032) Table 55. Global Myasthenia Gravis Drugs Price by Application (2021-2026) & (US$/Kg) Table 56. Global Myasthenia Gravis Drugs Price by Application (2027-2032) & (US$/Kg) Table 57. Alexion Pharmaceuticals Company Information Table 58. Alexion Pharmaceuticals Business Overview Table 59. Alexion Pharmaceuticals Myasthenia Gravis Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 60. Alexion Pharmaceuticals Myasthenia Gravis Drugs Product Portfolio Table 61. Alexion Pharmaceuticals Recent Development Table 62. Bausch Health Company Information Table 63. Bausch Health Business Overview Table 64. Bausch Health Myasthenia Gravis Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 65. Bausch Health Myasthenia Gravis Drugs Product Portfolio Table 66. Bausch Health Recent Development Table 67. Catalyst Pharmaceuticals Company Information Table 68. Catalyst Pharmaceuticals Business Overview Table 69. Catalyst Pharmaceuticals Myasthenia Gravis Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 70. Catalyst Pharmaceuticals Myasthenia Gravis Drugs Product Portfolio Table 71. Catalyst Pharmaceuticals Recent Development Table 72. CSL Company Information Table 73. CSL Business Overview Table 74. CSL Myasthenia Gravis Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 75. CSL Myasthenia Gravis Drugs Product Portfolio Table 76. CSL Recent Development Table 77. Curavac Company Information Table 78. Curavac Business Overview Table 79. Curavac Myasthenia Gravis Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 80. Curavac Myasthenia Gravis Drugs Product Portfolio Table 81. Curavac Recent Development Table 82. Cytokinetics Company Information Table 83. Cytokinetics Business Overview Table 84. Cytokinetics Myasthenia Gravis Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 85. Cytokinetics Myasthenia Gravis Drugs Product Portfolio Table 86. Cytokinetics Recent Development Table 87. F. Hoffmann-La Roche Company Information Table 88. F. Hoffmann-La Roche Business Overview Table 89. F. Hoffmann-La Roche Myasthenia Gravis Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 90. F. Hoffmann-La Roche Myasthenia Gravis Drugs Product Portfolio Table 91. F. Hoffmann-La Roche Recent Development Table 92. Flamel Technologies Company Information Table 93. Flamel Technologies Business Overview Table 94. Flamel Technologies Myasthenia Gravis Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 95. Flamel Technologies Myasthenia Gravis Drugs Product Portfolio Table 96. Flamel Technologies Recent Development Table 97. Galencia Company Information Table 98. Galencia Business Overview Table 99. Galencia Myasthenia Gravis Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 100. Galencia Myasthenia Gravis Drugs Product Portfolio Table 101. Galencia Recent Development Table 102. GlaxoSmithKline Company Information Table 103. GlaxoSmithKline Business Overview Table 104. GlaxoSmithKline Myasthenia Gravis Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 105. GlaxoSmithKline Myasthenia Gravis Drugs Product Portfolio Table 106. GlaxoSmithKline Recent Development Table 107. Grifols Company Information Table 108. Grifols Business Overview Table 109. Grifols Myasthenia Gravis Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 110. Grifols Myasthenia Gravis Drugs Product Portfolio Table 111. Grifols Recent Development Table 112. Lupin Pharmaceuticals Company Information Table 113. Lupin Pharmaceuticals Business Overview Table 114. Lupin Pharmaceuticals Myasthenia Gravis Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 115. Lupin Pharmaceuticals Myasthenia Gravis Drugs Product Portfolio Table 116. Lupin Pharmaceuticals Recent Development Table 117. Mitsubishi Tanabe Pharma Company Information Table 118. Mitsubishi Tanabe Pharma Business Overview Table 119. Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 120. Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Product Portfolio Table 121. Mitsubishi Tanabe Pharma Recent Development Table 122. Pfizer Company Information Table 123. Pfizer Business Overview Table 124. Pfizer Myasthenia Gravis Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 125. Pfizer Myasthenia Gravis Drugs Product Portfolio Table 126. Pfizer Recent Development Table 127. Novartis Company Information Table 128. Novartis Business Overview Table 129. Novartis Myasthenia Gravis Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 130. Novartis Myasthenia Gravis Drugs Product Portfolio Table 131. Novartis Recent Development Table 132. Takeda Company Information Table 133. Takeda Business Overview Table 134. Takeda Myasthenia Gravis Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 135. Takeda Myasthenia Gravis Drugs Product Portfolio Table 136. Takeda Recent Development Table 137. North America Myasthenia Gravis Drugs Revenue by Type (2021-2026) & (US$ Million) Table 138. North America Myasthenia Gravis Drugs Revenue by Type (2027-2032) & (US$ Million) Table 139. North America Myasthenia Gravis Drugs Sales by Type (2021-2026) & (Tons) Table 140. North America Myasthenia Gravis Drugs Sales by Type (2027-2032) & (Tons) Table 141. North America Myasthenia Gravis Drugs Sales Price by Type (2021-2026) & (US$/Kg) Table 142. North America Myasthenia Gravis Drugs Sales Price by Type (2027-2032) & (US$/Kg) Table 143. North America Myasthenia Gravis Drugs Revenue by Application (2021-2026) & (US$ Million) Table 144. North America Myasthenia Gravis Drugs Revenue by Application (2027-2032) & (US$ Million) Table 145. North America Myasthenia Gravis Drugs Sales by Application (2021-2026) & (Tons) Table 146. North America Myasthenia Gravis Drugs Sales by Application (2027-2032) & (Tons) Table 147. North America Myasthenia Gravis Drugs Sales Price by Application (2021-2026) & (US$/Kg) Table 148. North America Myasthenia Gravis Drugs Sales Price by Application (2027-2032) & (US$/Kg) Table 149. North America Myasthenia Gravis Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 150. North America Myasthenia Gravis Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 151. North America Myasthenia Gravis Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 152. North America Myasthenia Gravis Drugs Sales by Country (2021 VS 2025 VS 2032) & (Tons) Table 153. North America Myasthenia Gravis Drugs Sales by Country (2021-2026) & (Tons) Table 154. North America Myasthenia Gravis Drugs Sales by Country (2027-2032) & (Tons) Table 155. North America Myasthenia Gravis Drugs Sales Price by Country (2021-2026) & (US$/Kg) Table 156. North America Myasthenia Gravis Drugs Sales Price by Country (2027-2032) & (US$/Kg) Table 157. United States Myasthenia Gravis Drugs Revenue (2021-2032) & (US$ Million) Table 158. Canada Myasthenia Gravis Drugs Revenue (2021-2032) & (US$ Million) Table 159. Mexico Myasthenia Gravis Drugs Revenue (2021-2032) & (US$ Million) Table 160. Europe Myasthenia Gravis Drugs Revenue by Type (2021-2026) & (US$ Million) Table 161. Europe Myasthenia Gravis Drugs Revenue by Type (2027-2032) & (US$ Million) Table 162. Europe Myasthenia Gravis Drugs Sales by Type (2021-2026) & (Tons) Table 163. Europe Myasthenia Gravis Drugs Sales by Type (2027-2032) & (Tons) Table 164. Europe Myasthenia Gravis Drugs Sales Price by Type (2021-2026) & (US$/Kg) Table 165. Europe Myasthenia Gravis Drugs Sales Price by Type (2027-2032) & (US$/Kg) Table 166. Europe Myasthenia Gravis Drugs Revenue by Application (2021-2026) & (US$ Million) Table 167. Europe Myasthenia Gravis Drugs Revenue by Application (2027-2032) & (US$ Million) Table 168. Europe Myasthenia Gravis Drugs Sales by Application (2021-2026) & (Tons) Table 169. Europe Myasthenia Gravis Drugs Sales by Application (2027-2032) & (Tons) Table 170. Europe Myasthenia Gravis Drugs Sales Price by Application (2021-2026) & (US$/Kg) Table 171. Europe Myasthenia Gravis Drugs Sales Price by Application (2027-2032) & (US$/Kg) Table 172. Europe Myasthenia Gravis Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 173. Europe Myasthenia Gravis Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 174. Europe Myasthenia Gravis Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 175. Europe Myasthenia Gravis Drugs Sales by Country (2021 VS 2025 VS 2032) & (Tons) Table 176. Europe Myasthenia Gravis Drugs Sales by Country (2021-2026) & (Tons) Table 177. Europe Myasthenia Gravis Drugs Sales by Country (2027-2032) & (Tons) Table 178. Europe Myasthenia Gravis Drugs Sales Price by Country (2021-2026) & (US$/Kg) Table 179. Europe Myasthenia Gravis Drugs Sales Price by Country (2027-2032) & (US$/Kg) Table 180. Germany Myasthenia Gravis Drugs Revenue (2021-2032) & (US$ Million) Table 181. France Myasthenia Gravis Drugs Revenue (2021-2032) & (US$ Million) Table 182. U.K. Myasthenia Gravis Drugs Revenue (2021-2032) & (US$ Million) Table 183. Italy Myasthenia Gravis Drugs Revenue (2021-2032) & (US$ Million) Table 184. Russia Myasthenia Gravis Drugs Revenue (2021-2032) & (US$ Million) Table 185. Spain Myasthenia Gravis Drugs Revenue (2021-2032) & (US$ Million) Table 186. Netherlands Myasthenia Gravis Drugs Revenue (2021-2032) & (US$ Million) Table 187. Switzerland Myasthenia Gravis Drugs Revenue (2021-2032) & (US$ Million) Table 188. Sweden Myasthenia Gravis Drugs Revenue (2021-2032) & (US$ Million) Table 189. Poland Myasthenia Gravis Drugs Revenue (2021-2032) & (US$ Million) Table 190. China Myasthenia Gravis Drugs Revenue by Type (2021-2026) & (US$ Million) Table 191. China Myasthenia Gravis Drugs Revenue by Type (2027-2032) & (US$ Million) Table 192. China Myasthenia Gravis Drugs Sales by Type (2021-2026) & (Tons) Table 193. China Myasthenia Gravis Drugs Sales by Type (2027-2032) & (Tons) Table 194. China Myasthenia Gravis Drugs Sales Price by Type (2021-2026) & (US$/Kg) Table 195. China Myasthenia Gravis Drugs Sales Price by Type (2027-2032) & (US$/Kg) Table 196. China Myasthenia Gravis Drugs Revenue by Application (2021-2026) & (US$ Million) Table 197. China Myasthenia Gravis Drugs Revenue by Application (2027-2032) & (US$ Million) Table 198. China Myasthenia Gravis Drugs Sales by Application (2021-2026) & (Tons) Table 199. China Myasthenia Gravis Drugs Sales by Application (2027-2032) & (Tons) Table 200. China Myasthenia Gravis Drugs Sales Price by Application (2021-2026) & (US$/Kg) Table 201. China Myasthenia Gravis Drugs Sales Price by Application (2027-2032) & (US$/Kg) Table 202. Asia Myasthenia Gravis Drugs Revenue by Type (2021-2026) & (US$ Million) Table 203. Asia Myasthenia Gravis Drugs Revenue by Type (2027-2032) & (US$ Million) Table 204. Asia Myasthenia Gravis Drugs Sales by Type (2021-2026) & (Tons) Table 205. Asia Myasthenia Gravis Drugs Sales by Type (2027-2032) & (Tons) Table 206. Asia Myasthenia Gravis Drugs Sales Price by Type (2021-2026) & (US$/Kg) Table 207. Asia Myasthenia Gravis Drugs Sales Price by Type (2027-2032) & (US$/Kg) Table 208. Asia Myasthenia Gravis Drugs Revenue by Application (2021-2026) & (US$ Million) Table 209. Asia Myasthenia Gravis Drugs Revenue by Application (2027-2032) & (US$ Million) Table 210. Asia Myasthenia Gravis Drugs Sales by Application (2021-2026) & (Tons) Table 211. Asia Myasthenia Gravis Drugs Sales by Application (2027-2032) & (Tons) Table 212. Asia Myasthenia Gravis Drugs Sales Price by Application (2021-2026) & (US$/Kg) Table 213. Asia Myasthenia Gravis Drugs Sales Price by Application (2027-2032) & (US$/Kg) Table 214. Asia Myasthenia Gravis Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 215. Asia Myasthenia Gravis Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 216. Asia Myasthenia Gravis Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 217. Asia Myasthenia Gravis Drugs Sales by Country (2021 VS 2025 VS 2032) & (Tons) Table 218. Asia Myasthenia Gravis Drugs Sales by Country (2021-2026) & (Tons) Table 219. Asia Myasthenia Gravis Drugs Sales by Country (2027-2032) & (Tons) Table 220. Asia Myasthenia Gravis Drugs Sales Price by Country (2021-2026) & (US$/Kg) Table 221. Asia Myasthenia Gravis Drugs Sales Price by Country (2027-2032) & (US$/Kg) Table 222. Japan Myasthenia Gravis Drugs Revenue (2021-2032) & (US$ Million) Table 223. South Korea Myasthenia Gravis Drugs Revenue (2021-2032) & (US$ Million) Table 224. India Myasthenia Gravis Drugs Revenue (2021-2032) & (US$ Million) Table 225. Australia Myasthenia Gravis Drugs Revenue (2021-2032) & (US$ Million) Table 226. Taiwan Myasthenia Gravis Drugs Revenue (2021-2032) & (US$ Million) Table 227. Southeast Asia Myasthenia Gravis Drugs Revenue (2021-2032) & (US$ Million) Table 228. SAMEA Myasthenia Gravis Drugs Revenue by Type (2021-2026) & (US$ Million) Table 229. SAMEA Myasthenia Gravis Drugs Revenue by Type (2027-2032) & (US$ Million) Table 230. SAMEA Myasthenia Gravis Drugs Sales by Type (2021-2026) & (Tons) Table 231. SAMEA Myasthenia Gravis Drugs Sales by Type (2027-2032) & (Tons) Table 232. SAMEA Myasthenia Gravis Drugs Sales Price by Type (2021-2026) & (US$/Kg) Table 233. SAMEA Myasthenia Gravis Drugs Sales Price by Type (2027-2032) & (US$/Kg) Table 234. SAMEA Myasthenia Gravis Drugs Revenue by Application (2021-2026) & (US$ Million) Table 235. SAMEA Myasthenia Gravis Drugs Revenue by Application (2027-2032) & (US$ Million) Table 236. SAMEA Myasthenia Gravis Drugs Sales by Application (2021-2026) & (Tons) Table 237. SAMEA Myasthenia Gravis Drugs Sales by Application (2027-2032) & (Tons) Table 238. SAMEA Myasthenia Gravis Drugs Sales Price by Application (2021-2026) & (US$/Kg) Table 239. SAMEA Myasthenia Gravis Drugs Sales Price by Application (2027-2032) & (US$/Kg) Table 240. SAMEA Myasthenia Gravis Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 241. SAMEA Myasthenia Gravis Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 242. SAMEA Myasthenia Gravis Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 243. SAMEA Myasthenia Gravis Drugs Sales by Country (2021 VS 2025 VS 2032) & (Tons) Table 244. SAMEA Myasthenia Gravis Drugs Sales by Country (2021-2026) & (Tons) Table 245. SAMEA Myasthenia Gravis Drugs Sales by Country (2027-2032) & (Tons) Table 246. SAMEA Myasthenia Gravis Drugs Sales Price by Country (2021-2026) & (US$/Kg) Table 247. SAMEA Myasthenia Gravis Drugs Sales Price by Country (2027-2032) & (US$/Kg) Table 248. Brazil Myasthenia Gravis Drugs Revenue (2021-2032) & (US$ Million) Table 249. Argentina Myasthenia Gravis Drugs Revenue (2021-2032) & (US$ Million) Table 250. Chile Myasthenia Gravis Drugs Revenue (2021-2032) & (US$ Million) Table 251. Colombia Myasthenia Gravis Drugs Revenue (2021-2032) & (US$ Million) Table 252. Peru Myasthenia Gravis Drugs Revenue (2021-2032) & (US$ Million) Table 253. Saudi Arabia Myasthenia Gravis Drugs Revenue (2021-2032) & (US$ Million) Table 254. Israel Myasthenia Gravis Drugs Revenue (2021-2032) & (US$ Million) Table 255. UAE Myasthenia Gravis Drugs Revenue (2021-2032) & (US$ Million) Table 256. Turkey Myasthenia Gravis Drugs Revenue (2021-2032) & (US$ Million) Table 257. Iran Myasthenia Gravis Drugs Revenue (2021-2032) & (US$ Million) Table 258. Egypt Myasthenia Gravis Drugs Revenue (2021-2032) & (US$ Million) Table 259. Key Raw Materials Table 260. Raw Materials Key Suppliers Table 261. Myasthenia Gravis Drugs Distributors List Table 262. Myasthenia Gravis Drugs Customers List Table 263. Research Programs/Design for This Report Table 264. Authors List of This Report Table 265. Secondary Sources Table 266. Primary Sources List of Figures Figure 1. Myasthenia Gravis Drugs Image Figure 2. Global Myasthenia Gravis Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Myasthenia Gravis Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Intravenous Immune Globulins Image Figure 5. Anticholinesterases Image Figure 6. Immunosuppressants Image Figure 7. Global Myasthenia Gravis Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Myasthenia Gravis Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospitals Image Figure 10. Clinics Image Figure 11. Global Myasthenia Gravis Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Myasthenia Gravis Drugs Revenue (2021-2032) & (US$ Million) Figure 13. Global Myasthenia Gravis Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global Myasthenia Gravis Drugs Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global Myasthenia Gravis Drugs Revenue Market Share by Region (2021-2032) Figure 16. Global Myasthenia Gravis Drugs Sales (2021-2032) & (Tons) Figure 17. Global Myasthenia Gravis Drugs Sales by Region: 2021 VS 2025 VS 2032 (Tons) Figure 18. Global Myasthenia Gravis Drugs Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico Myasthenia Gravis Drugs Sales YoY (2021-2032) & (Tons) Figure 20. Europe Myasthenia Gravis Drugs Sales YoY (2021-2032) & (Tons) Figure 21. China Myasthenia Gravis Drugs Sales YoY (2021-2032) & (Tons) Figure 22. Asia (Excluding China) Myasthenia Gravis Drugs Sales YoY (2021-2032) & (Tons) Figure 23. South America, Middle East and Africa Myasthenia Gravis Drugs Sales YoY (2021-2032) & (Tons) Figure 24. Global Myasthenia Gravis Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global Myasthenia Gravis Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global Myasthenia Gravis Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Myasthenia Gravis Drugs Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global Myasthenia Gravis Drugs Revenue Market Share by Type (2021-2032) Figure 30. Global Myasthenia Gravis Drugs Sales by Type (2021 VS 2025 VS 2032) & (Tons) Figure 31. Global Myasthenia Gravis Drugs Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Myasthenia Gravis Drugs Sales Market Share by Type (2021-2032) Figure 33. Global Myasthenia Gravis Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Myasthenia Gravis Drugs Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global Myasthenia Gravis Drugs Revenue Market Share by Application (2021-2032) Figure 36. Global Myasthenia Gravis Drugs Sales by Application (2021 VS 2025 VS 2032) & (Tons) Figure 37. Global Myasthenia Gravis Drugs Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Myasthenia Gravis Drugs Sales Market Share by Application (2021-2032) Figure 39. North America Myasthenia Gravis Drugs Revenue Share by Type (2021-2032) Figure 40. North America Myasthenia Gravis Drugs Sales Share by Type (2021-2032) Figure 41. North America Myasthenia Gravis Drugs Revenue Share by Application (2021-2032) Figure 42. North America Myasthenia Gravis Drugs Sales Share by Application (2021-2032) Figure 43. North America Myasthenia Gravis Drugs Revenue Share by Country (2021-2032) Figure 44. North America Myasthenia Gravis Drugs Sales Share by Country (2021-2032) Figure 45. Europe Myasthenia Gravis Drugs Revenue Share by Type (2021-2032) Figure 46. Europe Myasthenia Gravis Drugs Sales Share by Type (2021-2032) Figure 47. Europe Myasthenia Gravis Drugs Revenue Share by Application (2021-2032) Figure 48. Europe Myasthenia Gravis Drugs Sales Share by Application (2021-2032) Figure 49. Europe Myasthenia Gravis Drugs Revenue Share by Country (2021-2032) Figure 50. Europe Myasthenia Gravis Drugs Sales Share by Country (2021-2032) Figure 51. China Myasthenia Gravis Drugs Revenue Share by Type (2021-2032) Figure 52. China Myasthenia Gravis Drugs Sales Share by Type (2021-2032) Figure 53. China Myasthenia Gravis Drugs Revenue Share by Application (2021-2032) Figure 54. China Myasthenia Gravis Drugs Sales Share by Application (2021-2032) Figure 55. Asia Myasthenia Gravis Drugs Revenue Share by Type (2021-2032) Figure 56. Asia Myasthenia Gravis Drugs Sales Share by Type (2021-2032) Figure 57. Asia Myasthenia Gravis Drugs Revenue Share by Application (2021-2032) Figure 58. Asia Myasthenia Gravis Drugs Sales Share by Application (2021-2032) Figure 59. Asia Myasthenia Gravis Drugs Revenue Share by Country (2021-2032) Figure 60. Asia Myasthenia Gravis Drugs Sales Share by Country (2021-2032) Figure 61. SAMEA Myasthenia Gravis Drugs Revenue Share by Type (2021-2032) Figure 62. SAMEA Myasthenia Gravis Drugs Sales Share by Type (2021-2032) Figure 63. SAMEA Myasthenia Gravis Drugs Revenue Share by Application (2021-2032) Figure 64. SAMEA Myasthenia Gravis Drugs Sales Share by Application (2021-2032) Figure 65. SAMEA Myasthenia Gravis Drugs Revenue Share by Country (2021-2032) Figure 66. SAMEA Myasthenia Gravis Drugs Sales Share by Country (2021-2032) Figure 67. Myasthenia Gravis Drugs Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Myasthenia Gravis Drugs Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Intravenous Immune Globulins
  • Anticholinesterases
  • Immunosuppressants
Applications
  • Hospitals
  • Clinics
Companies covered
  • Alexion Pharmaceuticals
  • Bausch Health
  • Catalyst Pharmaceuticals
  • CSL
  • Curavac
  • Cytokinetics
  • F. Hoffmann-La Roche
  • Flamel Technologies
  • Galencia
  • GlaxoSmithKline
  • Grifols
  • Lupin Pharmaceuticals
  • Mitsubishi Tanabe Pharma
  • Pfizer
  • Novartis
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Myasthenia Gravis Drugs Market by Type
  3. 1.2.1 Global Myasthenia Gravis Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Intravenous Immune Globulins
  5. 1.2.3 Anticholinesterases
  6. 1.2.4 Immunosuppressants
  7. 1.3 Myasthenia Gravis Drugs Market by Application
  8. 1.3.1 Global Myasthenia Gravis Drugs Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospitals
  10. 1.3.3 Clinics
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Myasthenia Gravis Drugs Market Dynamics
  1. 2.1 Myasthenia Gravis Drugs Industry Trends
  2. 2.2 Myasthenia Gravis Drugs Industry Drivers
  3. 2.3 Myasthenia Gravis Drugs Industry Opportunities and Challenges
  4. 2.4 Myasthenia Gravis Drugs Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Myasthenia Gravis Drugs Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Myasthenia Gravis Drugs Revenue by Region
  3. 3.2.1 Global Myasthenia Gravis Drugs Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Myasthenia Gravis Drugs Revenue by Region (2021-2026)
  5. 3.2.3 Global Myasthenia Gravis Drugs Revenue by Region (2027-2032)
  6. 3.2.4 Global Myasthenia Gravis Drugs Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Myasthenia Gravis Drugs Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Myasthenia Gravis Drugs Sales by Region
  9. 3.4.1 Global Myasthenia Gravis Drugs Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Myasthenia Gravis Drugs Sales by Region (2021-2026)
  11. 3.4.3 Global Myasthenia Gravis Drugs Sales by Region (2027-2032)
  12. 3.4.4 Global Myasthenia Gravis Drugs Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Myasthenia Gravis Drugs Revenue by Manufacturers
  2. 4.1.1 Global Myasthenia Gravis Drugs Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Myasthenia Gravis Drugs Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Myasthenia Gravis Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Myasthenia Gravis Drugs Sales by Manufacturers
  6. 4.2.1 Global Myasthenia Gravis Drugs Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Myasthenia Gravis Drugs Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Myasthenia Gravis Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Myasthenia Gravis Drugs Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Myasthenia Gravis Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Myasthenia Gravis Drugs Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Myasthenia Gravis Drugs Manufacturers, Product Type & Application
  13. 4.7 Global Myasthenia Gravis Drugs Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Myasthenia Gravis Drugs Market CR5 and HHI
  16. 4.8.2 2025 Myasthenia Gravis Drugs Tier 1, Tier 2, and Tier 3
5 Myasthenia Gravis Drugs Market by Type
  1. 5.1 Global Myasthenia Gravis Drugs Revenue by Type
  2. 5.1.1 Global Myasthenia Gravis Drugs Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Myasthenia Gravis Drugs Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Myasthenia Gravis Drugs Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Myasthenia Gravis Drugs Sales by Type
  6. 5.2.1 Global Myasthenia Gravis Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Myasthenia Gravis Drugs Sales by Type (2021-2032) & (Tons)
  8. 5.2.3 Global Myasthenia Gravis Drugs Sales Market Share by Type (2021-2032)
  9. 5.3 Global Myasthenia Gravis Drugs Price by Type
6 Myasthenia Gravis Drugs Market by Application
  1. 6.1 Global Myasthenia Gravis Drugs Revenue by Application
  2. 6.1.1 Global Myasthenia Gravis Drugs Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Myasthenia Gravis Drugs Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Myasthenia Gravis Drugs Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Myasthenia Gravis Drugs Sales by Application
  6. 6.2.1 Global Myasthenia Gravis Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Myasthenia Gravis Drugs Sales by Application (2021-2032) & (Tons)
  8. 6.2.3 Global Myasthenia Gravis Drugs Sales Market Share by Application (2021-2032)
  9. 6.3 Global Myasthenia Gravis Drugs Price by Application
7 Company Profiles
  1. 7.1 Alexion Pharmaceuticals
  2. 7.1.1 Alexion Pharmaceuticals Company Information
  3. 7.1.2 Alexion Pharmaceuticals Business Overview
  4. 7.1.3 Alexion Pharmaceuticals Myasthenia Gravis Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Alexion Pharmaceuticals Myasthenia Gravis Drugs Product Portfolio
  6. 7.1.5 Alexion Pharmaceuticals Recent Developments
  7. 7.2 Bausch Health
  8. 7.2.1 Bausch Health Company Information
  9. 7.2.2 Bausch Health Business Overview
  10. 7.2.3 Bausch Health Myasthenia Gravis Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Bausch Health Myasthenia Gravis Drugs Product Portfolio
  12. 7.2.5 Bausch Health Recent Developments
  13. 7.3 Catalyst Pharmaceuticals
  14. 7.3.1 Catalyst Pharmaceuticals Company Information
  15. 7.3.2 Catalyst Pharmaceuticals Business Overview
  16. 7.3.3 Catalyst Pharmaceuticals Myasthenia Gravis Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Catalyst Pharmaceuticals Myasthenia Gravis Drugs Product Portfolio
  18. 7.3.5 Catalyst Pharmaceuticals Recent Developments
  19. 7.4 CSL
  20. 7.4.1 CSL Company Information
  21. 7.4.2 CSL Business Overview
  22. 7.4.3 CSL Myasthenia Gravis Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 CSL Myasthenia Gravis Drugs Product Portfolio
  24. 7.4.5 CSL Recent Developments
  25. 7.5 Curavac
  26. 7.5.1 Curavac Company Information
  27. 7.5.2 Curavac Business Overview
  28. 7.5.3 Curavac Myasthenia Gravis Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Curavac Myasthenia Gravis Drugs Product Portfolio
  30. 7.5.5 Curavac Recent Developments
  31. 7.6 Cytokinetics
  32. 7.6.1 Cytokinetics Company Information
  33. 7.6.2 Cytokinetics Business Overview
  34. 7.6.3 Cytokinetics Myasthenia Gravis Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Cytokinetics Myasthenia Gravis Drugs Product Portfolio
  36. 7.6.5 Cytokinetics Recent Developments
  37. 7.7 F. Hoffmann-La Roche
  38. 7.7.1 F. Hoffmann-La Roche Company Information
  39. 7.7.2 F. Hoffmann-La Roche Business Overview
  40. 7.7.3 F. Hoffmann-La Roche Myasthenia Gravis Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 F. Hoffmann-La Roche Myasthenia Gravis Drugs Product Portfolio
  42. 7.7.5 F. Hoffmann-La Roche Recent Developments
  43. 7.8 Flamel Technologies
  44. 7.8.1 Flamel Technologies Company Information
  45. 7.8.2 Flamel Technologies Business Overview
  46. 7.8.3 Flamel Technologies Myasthenia Gravis Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Flamel Technologies Myasthenia Gravis Drugs Product Portfolio
  48. 7.8.5 Flamel Technologies Recent Developments
  49. 7.9 Galencia
  50. 7.9.1 Galencia Company Information
  51. 7.9.2 Galencia Business Overview
  52. 7.9.3 Galencia Myasthenia Gravis Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Galencia Myasthenia Gravis Drugs Product Portfolio
  54. 7.9.5 Galencia Recent Developments
  55. 7.10 GlaxoSmithKline
  56. 7.10.1 GlaxoSmithKline Company Information
  57. 7.10.2 GlaxoSmithKline Business Overview
  58. 7.10.3 GlaxoSmithKline Myasthenia Gravis Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 GlaxoSmithKline Myasthenia Gravis Drugs Product Portfolio
  60. 7.10.5 GlaxoSmithKline Recent Developments
  61. 7.11 Grifols
  62. 7.11.1 Grifols Company Information
  63. 7.11.2 Grifols Business Overview
  64. 7.11.3 Grifols Myasthenia Gravis Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Grifols Myasthenia Gravis Drugs Product Portfolio
  66. 7.11.5 Grifols Recent Developments
  67. 7.12 Lupin Pharmaceuticals
  68. 7.12.1 Lupin Pharmaceuticals Company Information
  69. 7.12.2 Lupin Pharmaceuticals Business Overview
  70. 7.12.3 Lupin Pharmaceuticals Myasthenia Gravis Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Lupin Pharmaceuticals Myasthenia Gravis Drugs Product Portfolio
  72. 7.12.5 Lupin Pharmaceuticals Recent Developments
  73. 7.13 Mitsubishi Tanabe Pharma
  74. 7.13.1 Mitsubishi Tanabe Pharma Company Information
  75. 7.13.2 Mitsubishi Tanabe Pharma Business Overview
  76. 7.13.3 Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Product Portfolio
  78. 7.13.5 Mitsubishi Tanabe Pharma Recent Developments
  79. 7.14 Pfizer
  80. 7.14.1 Pfizer Company Information
  81. 7.14.2 Pfizer Business Overview
  82. 7.14.3 Pfizer Myasthenia Gravis Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Pfizer Myasthenia Gravis Drugs Product Portfolio
  84. 7.14.5 Pfizer Recent Developments
  85. 7.15 Novartis
  86. 7.15.1 Novartis Company Information
  87. 7.15.2 Novartis Business Overview
  88. 7.15.3 Novartis Myasthenia Gravis Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Novartis Myasthenia Gravis Drugs Product Portfolio
  90. 7.15.5 Novartis Recent Developments
  91. 7.16 Takeda
  92. 7.16.1 Takeda Company Information
  93. 7.16.2 Takeda Business Overview
  94. 7.16.3 Takeda Myasthenia Gravis Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Takeda Myasthenia Gravis Drugs Product Portfolio
  96. 7.16.5 Takeda Recent Developments
8 North America
  1. 8.1 North America Myasthenia Gravis Drugs Market Size by Type
  2. 8.1.1 North America Myasthenia Gravis Drugs Revenue by Type (2021-2032)
  3. 8.1.2 North America Myasthenia Gravis Drugs Sales by Type (2021-2032)
  4. 8.1.3 North America Myasthenia Gravis Drugs Price by Type (2021-2032)
  5. 8.2 North America Myasthenia Gravis Drugs Market Size by Application
  6. 8.2.1 North America Myasthenia Gravis Drugs Revenue by Application (2021-2032)
  7. 8.2.2 North America Myasthenia Gravis Drugs Sales by Application (2021-2032)
  8. 8.2.3 North America Myasthenia Gravis Drugs Price by Application (2021-2032)
  9. 8.3 North America Myasthenia Gravis Drugs Market Size by Country
  10. 8.3.1 North America Myasthenia Gravis Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Myasthenia Gravis Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Myasthenia Gravis Drugs Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Myasthenia Gravis Drugs Market Size by Type
  2. 9.1.1 Europe Myasthenia Gravis Drugs Revenue by Type (2021-2032)
  3. 9.1.2 Europe Myasthenia Gravis Drugs Sales by Type (2021-2032)
  4. 9.1.3 Europe Myasthenia Gravis Drugs Price by Type (2021-2032)
  5. 9.2 Europe Myasthenia Gravis Drugs Market Size by Application
  6. 9.2.1 Europe Myasthenia Gravis Drugs Revenue by Application (2021-2032)
  7. 9.2.2 Europe Myasthenia Gravis Drugs Sales by Application (2021-2032)
  8. 9.2.3 Europe Myasthenia Gravis Drugs Price by Application (2021-2032)
  9. 9.3 Europe Myasthenia Gravis Drugs Market Size by Country
  10. 9.3.1 Europe Myasthenia Gravis Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Myasthenia Gravis Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Myasthenia Gravis Drugs Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Myasthenia Gravis Drugs Market Size by Type
  2. 10.1.1 China Myasthenia Gravis Drugs Revenue by Type (2021-2032)
  3. 10.1.2 China Myasthenia Gravis Drugs Sales by Type (2021-2032)
  4. 10.1.3 China Myasthenia Gravis Drugs Price by Type (2021-2032)
  5. 10.2 China Myasthenia Gravis Drugs Market Size by Application
  6. 10.2.1 China Myasthenia Gravis Drugs Revenue by Application (2021-2032)
  7. 10.2.2 China Myasthenia Gravis Drugs Sales by Application (2021-2032)
  8. 10.2.3 China Myasthenia Gravis Drugs Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Myasthenia Gravis Drugs Market Size by Type
  2. 11.1.1 Asia Myasthenia Gravis Drugs Revenue by Type (2021-2032)
  3. 11.1.2 Asia Myasthenia Gravis Drugs Sales by Type (2021-2032)
  4. 11.1.3 Asia Myasthenia Gravis Drugs Price by Type (2021-2032)
  5. 11.2 Asia Myasthenia Gravis Drugs Market Size by Application
  6. 11.2.1 Asia Myasthenia Gravis Drugs Revenue by Application (2021-2032)
  7. 11.2.2 Asia Myasthenia Gravis Drugs Sales by Application (2021-2032)
  8. 11.2.3 Asia Myasthenia Gravis Drugs Price by Application (2021-2032)
  9. 11.3 Asia Myasthenia Gravis Drugs Market Size by Country
  10. 11.3.1 Asia Myasthenia Gravis Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Myasthenia Gravis Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Myasthenia Gravis Drugs Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Myasthenia Gravis Drugs Market Size by Type
  2. 12.1.1 SAMEA Myasthenia Gravis Drugs Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Myasthenia Gravis Drugs Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Myasthenia Gravis Drugs Price by Type (2021-2032)
  5. 12.2 SAMEA Myasthenia Gravis Drugs Market Size by Application
  6. 12.2.1 SAMEA Myasthenia Gravis Drugs Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Myasthenia Gravis Drugs Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Myasthenia Gravis Drugs Price by Application (2021-2032)
  9. 12.3 SAMEA Myasthenia Gravis Drugs Market Size by Country
  10. 12.3.1 SAMEA Myasthenia Gravis Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Myasthenia Gravis Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Myasthenia Gravis Drugs Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Myasthenia Gravis Drugs Value Chain Analysis
  2. 13.1.1 Myasthenia Gravis Drugs Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Myasthenia Gravis Drugs Production Mode & Process
  6. 13.2 Myasthenia Gravis Drugs Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Myasthenia Gravis Drugs Distributors
  9. 13.2.3 Myasthenia Gravis Drugs Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst